Elotuzumab for the treatment of multiple myeloma
Abstract Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma act...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2016-07-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://link.springer.com/article/10.1186/s13045-016-0284-z |